Key clinical point: Romosozumab therapy may be associated with a reduction in the risk of falls in postmenopausal women with osteoporosis.
Major finding: Twelve-month treatment with romosozumab was associated with a nonsignificant reduction in the risk of falls by 16% (risk ratio [RR], 0.84; 95% confidence interval, 0.67-1.04). In contrast, the subgroup analysis with double-blind studies revealed a statistically significant 20% reduction in the risk of falls (RR, 0.80; 95% confidence interval, 0.71-0.92).
Study details: Meta-analysis of 4 studies including 12,128 postmenopausal women with osteoporosis.
Disclosures: No study sponsor was identified. Luis Möckel is a former employee of UCB Pharma and received fees for consultancy and presentations from UCB Pharma GmbH. The remaining authors declared no conflict of interest.
Möckel L et al. Osteoporos Sarcopenia. 2020 Feb 25. doi: 10.1016/j.afos.2020.02.003.